SCHEMBL3907353

SCHEMBL3907353

CCCC(Cl)(CO)CCC

nearest known ligand 0.35

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5528191 0.79 FDPS (0.35) FDPS
SCHEMBL8546930 0.78 HMGCR (0.36) FDPS
SCHEMBL27712336 0.76 FDPS (0.33) FDPS
Ammonia Solution, Strong SCHEMBL5924726 0.76 FDPS (0.33) FDPS
SCHEMBL8722255 0.75
SCHEMBL9618159 0.73
SCHEMBL11279692 0.73 FDPS (0.32) FDPS
SCHEMBL11284644 0.73
SCHEMBL10999172 0.73 LMNA (0.43) FDPS
SCHEMBL29323360 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569608-B2 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2009-08-04 US disclosed
US-7569609-B2 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2009-08-04 US disclosed
US-7176240-B2 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-13 US disclosed
US-20050267168-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2005-12-01 US disclosed
US-20050267167-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2005-12-01 US disclosed
US-20050261371-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2005-11-24 US disclosed
US-20030096802-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. 2003-05-22 US disclosed
US-6201021-B1 TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES ONO PHARMACEUTICAL CO., LTD. (JP) 2001-03-13 US disclosed
EP-0632008-B1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO (JP) 1998-02-04 EP disclosed
EP-0632008-A1 Pentanoic acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1995-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267168-A1 Pentanoic acid derivatives FFAR3, FFAR1, HCAR3 FDPS 3544/4885
US-20030096802-A1 Pentanoic acid derivatives FFAR3, FPR1, FPR3 FDPS 3647/4885
US-20050267167-A1 Pentanoic acid derivatives FFAR3, FFAR1, HCAR3 FDPS 3544/4885
US-20050261371-A1 Pentanoic acid derivatives FFAR3, FFAR1, HCAR3 FDPS 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.